Correlation between endothelial cell-specific molecule-1，sphingosine 1-phosphate receptor 3 and the severity and prognosis of Mycoplasma pneumonia pneumonia

doi:10.3969/j.issn.1673-8640.2026.03.006

Abstract

Abstract:

Objective To investigate the relationship between endothelial cell-specific molecule-1（ESM-1），sphingosine 1-phosphate receptor 3（S1PR3）and the severity of Mycoplasma pneumonia pneumonia（MPP）in children，as well as their value in prognosis assessment. Methods A total of 106 children with MPP（MPP group）and 106 healthy children（healthy control group）were enrolled from Ankang Maternal and Child Health Hospital from January 2021 to January 2024. All the MPP children were classified into severe group（69 cases）and mild group（37 cases）according to the clinical pulmonary infection score（CPIS）and clinical symptoms. All the children were classified into good prognosis group（64 cases）and poor prognosis group（42 cases）according to the CPIS score after one course of treatment. The levels of serum ESM-1 and S1PR3 and the pulmonary function indicators [time to peak tidal expiratory flow（TPTEF/Te%），volume at peak tidal expiratory flow（VPTEF/VT%）and respiratory rate（RR）] were determined. Pearson or Spearman correlation analysis was used to evaluate the correlation between various indicators. Logistic regression analysis was used to assess the influencing factors of poor prognosis in MPP children. Receiver operating characteristic（ROC）curve was used to evaluate the efficacy of various indicators in predicting poor prognosis of MPP children. Results The serum ESM-1 and S1PR3 levels in MPP group were higher than those in control group（p<0.001）. The ESM-1，S1PR3 and RR in severe group were higher than those in mild group（P<0.001），while TPTEF/Te%，VT and VPTEF/VT% were lower in severe group（P<0.05）. The serum ESM-1 and S1PR3 levels of MPP children were positively correlated with RR and disease severity（P<0.001），and they were negatively correlated with TPTEF/Te%，VT and VPTEF/VT%（p<0.001）. The serum ESM-1，S1PR3 levels and the proportion of bronchial inflation signs in poor prognosis group were higher than those in good prognosis group（P<0.001）. ESM-1 and S1PR3 were independent risk factors for poor prognosis in MPP children [odds ratios（OR）were 2.985 and 2.832，95% confidence intervals（CI）were 1.563-5.700 and 1.452-5.525，respectively，P<0.01]. The areas under curves（AUC）of ESM-1，S1PR3 single and combined determinations for predicting poor prognosis of MPP children were 0.856，0.855 and 0.939，respectively. Conclusions The serum ESM-1 and S1PR3 levels in MPP children are increased and are related to the disease severity. The combined determination of ESM-1 and S1PR3 has a predictive value for the prognosis of MPP children.

Key words: Endothelial cell-specific molecule-1, Sphingosine 1-phosphate receptor 3, Mycoplasma pneumonia pneumonia

CLC Number:

R446.1

MA Xiaomiao, LIU Feng, CHEN Fenting. Correlation between endothelial cell-specific molecule-1，sphingosine 1-phosphate receptor 3 and the severity and prognosis of Mycoplasma pneumonia pneumonia[J]. Laboratory Medicine, 2026, 41(3): 245-250.

Figures/Tables 8

References 22

[1]	翟斌, 韩梅. 肺炎支原体肺炎患儿血清miR-21、miR-146a表达变化及其与炎症因子的相关性[J]. 检验医学, 2024, 39(8):787-792. DOI
[2]	周丽娟, 吴艳凌, 周林, 等. 检测肺炎支原体新方法的建立及应用[J]. 实用临床医药杂志, 2022, 26(19):100-104.
[3]	SONG Z, JIA G, LUO G, et al. Global research trends of Mycoplasma pneumoniae pneumonia in children:a bibliometric analysis[J]. Front Pediatr, 2023, 11:1306234.
[4]	LI D, GU H, CHEN L, et al. Neutrophil-to-lymphocyte ratio as a predictor of poor outcomes of Mycoplasma pneumoniae pneumonia[J]. Front Immunol, 2023, 14:1302702.
[5]	邱崇荣, 彭金亮, 肖小六, 等. 血清endocan水平在老年社区获得性肺炎病情及预后评估的价值[J]. 江西医药, 2022, 57(8):853-855.
[6]	GUZEL D, KALKAN E A, EREN F, et al. Can serum endocan levels be used as an early prognostic marker for endothelial dysfunction in COVID-19?[J]. Angiology, 2022, 73(5):438-444. DOI URL
[7]	WU J, LIANG Y, FU P, et al. Sphingosine-1-phosphate receptor 3 induces endothelial barrier loss via ADAM10-mediated vascular endothelial-cadherin cleavage[J]. Int J Mol Sci, 2023, 24(22):16083. DOI URL
[8]	吴晓娜, 刘娜. 小儿肺炎临床诊疗[M]. 北京: 人民军医出版社, 2014.
[9]	蒋欢欢, 葛金林, 曾余丰. 肺炎支原体合并链球菌感染肺炎IL-10和IL-17及淋巴细胞亚群与预后的关系[J]. 中华医院感染学杂志, 2025, 35(3):331-335.
[10]	中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 新发传染病电子杂志, 2024, 9(1):73-79. DOI
[11]	FAN F, LV J, YANG Q, et al. Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children[J]. Clin Respir J, 2023, 17(7):607-617. DOI PMID
[12]	LUO X Q, LUO J, WANG C J, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood:a retrospective study[J]. Pediatr Pulmonol, 2023, 58(10):2815-2822. DOI URL
[13]	翁翠琦, 陈玉梅, 蒋蕾, 等. 小儿肺炎支原体肺炎血清CRP、PCT、ESR水平与病情严重程度的关系[J]. 中华医院感染学杂志, 2022, 32(8):1220-1223.
[14]	HUREAU M, PORTIER L, PRIN M, et al. Evaluation of endocan as a treatment for acute inflammatory respiratory failure[J]. Cells, 2023, 12(2):257. DOI URL
[15]	KHALAJI A, AMIRKHANI N, SHARIFKASHANI S, et al. Systematic review of endocan as a potential biomarker of COVID-19[J]. Angiology, 2024, 75(2):107-115. DOI URL
[16]	栾海丽, 秦可佳, 段然. 血清 Endocan、补体C3a与重症肺炎患儿病情和预后转归的关系分析[J]. 中国妇幼健康研究, 2024, 35(6):89-95.
[17]	TAŞAR S, FIDANCI İ, BULUT İ, et al. Role of serum endocan levels in children with bacterial and viral pneumonia:a prospective,case-control study[J]. Pediatr Allergy Immunol Pulmonol, 2022, 35(4):145-152. DOI URL
[18]	TERLIZZI M, COLARUSSO C, SOMMA P, et al. S1P-induced TNF-α and IL-6 release from PBMCs exacerbates lung cancer-associated inflammation[J]. Cells, 2022, 11(16):2524. DOI URL
[19]	PENG J, TANG R, HE J, et al. S1PR3 inhibition protects against LPS-induced ARDS by inhibiting NF-κB and improving mitochondrial oxidative phosphorylation[J]. J Transl Med, 2024, 22(1):535. DOI PMID
[20]	WU J, LIANG Y, FENG A, et al. S1PR3 plays a key role in ventilator-induced lung injury:promoter activation,barrier disruption,and therapeutic evaluation[J]. Free Radic Biol Med, 2022, 192(1):75-76.
[21]	李荣, 丘向燕, 刘玉娜, 等. 重症社区获得性肺炎患者血清1磷酸鞘氨醇受体3水平的变化及临床意义[J]. 医药前沿, 2023, 13(12):7-9.
[22]	PIAO J, SU Z, HE J, et al. SphK1 deficiency ameliorates the development of atherosclerosis by inhibiting the S1P/S1PR3/Rhoa/ROCK pathway[J]. Cell Signal, 2024, 121:111252.

组别	例数	ESM-1/（ng·mL^-1）	S1PR3/（ng·mL^-1）
正常对照组	106	4.15±1.63	3.75±0.89
MPP组	106	14.92±4.45	23.54±7.12
t值		23.398	28.396
P值		<0.001	<0.001

组别	例数	ESM-1/（ng·mL^-1）	S1PR3/（ng·mL^-1）
正常对照组	106	4.15±1.63	3.75±0.89
MPP组	106	14.92±4.45	23.54±7.12
t值		23.398	28.396
P值		<0.001	<0.001

组别	例数	ESM-1/（ng·mL^-1）	S1PR3/（ng·mL^-1）	TPTEF/Te%/%	RR/（次·分^-1）	VT/（mL·kg^-1）	VPTEF/VT%/%
轻症组	37	9.04±3.02	13.19±4.75	27.14±4.36	27.15±2.76	7.65±1.21	28.94±3.76
重症组	69	18.07±5.12	29.09±8.94	18.35±2.69	29.13±2.85	7.24±0.82	22.35±3.91
t值		9.837	10.068	12.826	3.447	2.068	8.381
P值		<0.001	<0.001	<0.001	<0.001	0.041	<0.001

组别	例数	ESM-1/（ng·mL^-1）	S1PR3/（ng·mL^-1）	TPTEF/Te%/%	RR/（次·分^-1）	VT/（mL·kg^-1）	VPTEF/VT%/%
轻症组	37	9.04±3.02	13.19±4.75	27.14±4.36	27.15±2.76	7.65±1.21	28.94±3.76
重症组	69	18.07±5.12	29.09±8.94	18.35±2.69	29.13±2.85	7.24±0.82	22.35±3.91
t值		9.837	10.068	12.826	3.447	2.068	8.381
P值		<0.001	<0.001	<0.001	<0.001	0.041	<0.001

组别	例数	性别		年龄/岁	胸腔积液/[例（%）]	肺实变影/[例（%）]	支气管充气征/[例（%）]	发热时间/d
组别	例数	男/[例（%）]	女/[例（%）]	年龄/岁	胸腔积液/[例（%）]	肺实变影/[例（%）]	支气管充气征/[例（%）]	发热时间/d
预后良好组	64	30（46.88）	34（53.12）	5.50±2.02	13（20.31）	57（89.06）	28（43.75）	5.45±1.25
预后不良组	42	21（50.00）	21（50.00）	5.62±2.10	14（33.33）	40（95.24）	35（83.33）	5.60±1.38
统计值		0.099		0.294	2.265	0.577	16.480	0.580
P值		0.753		0.769	0.132	0.448	<0.001	0.563
组别	CRP/（mg·L^-1）	IL-6/（ng·L^-1）		TNF-α/（ng·L^-1）	PLT计数/（×10⁹L^-1）	WBC计数/（×10⁹L^-1）	组别	CRP/（mg·L^-1）
预后良好组	21.75±6.10	34.81±8.60		19.38±5.06	248.72±49.36	10.95±2.72	预后良好组	21.75±6.10
预后不良组	22.89±6.42	36.98±8.56		20.75±4.92	257.93±51.60	10.81±2.69	预后不良组	22.89±6.42
统计值	0.922	1.273		1.378	0.923	0.260	统计值	0.922
P值	0.359	0.206		0.171	0.358	0.795	P值	0.359